Share Price and Basic Stock Data
Last Updated: December 5, 2025, 7:43 pm
| PEG Ratio | -5.36 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Concord Drugs Ltd operates within the pharmaceuticals sector, a space often characterized by steady demand yet significant competition. As of the latest reports, the company’s share price stood at ₹75.5, reflecting a market capitalization of ₹75.5 Cr. Revenue trends have shown fluctuations over recent quarters. For instance, sales peaked at ₹13.72 Cr in September 2022 but saw a decline to ₹7.38 Cr by September 2023. The trailing twelve months (TTM) sales reached ₹43.95 Cr, indicating a slight dip from ₹51.31 Cr in the previous fiscal year. Such variability may raise concerns about the company’s ability to maintain consistent revenue streams, crucial for long-term sustainability. The company’s operational performance is notably impacted by its cash conversion cycle, which currently stands at a prolonged 332.82 days, hinting at potential inefficiencies in managing receivables and inventory.
Profitability and Efficiency Metrics
When evaluating profitability, Concord Drugs’ operating profit margin (OPM) has shown a mixed performance, recorded at 7.03% recently, with a notable spike to 15.93% in June 2023. However, this was followed by a decline to 4.44% in December 2023, suggesting volatility in operational efficiency. Net profit margins have also faced challenges, with figures dropping to negative territory at various points, such as a reported loss of ₹0.24 Cr in December 2023. This inconsistency may raise red flags for investors regarding the company’s capacity to convert sales into sustainable profits. The return on equity (ROE) at 0.88% and return on capital employed (ROCE) at 4.73% further emphasize the need for improved operational strategies to enhance profitability, particularly in a sector where margins can be tight.
Balance Sheet Strength and Financial Ratios
Concord Drugs’ balance sheet reveals a mixed picture of financial health. With total borrowings at ₹16.91 Cr against reserves of ₹24.11 Cr, the leverage appears manageable, as evidenced by a debt-to-equity ratio of 0.50. However, the current ratio of 1.56 signals that while the company has sufficient liquid assets to cover short-term liabilities, it may still be vulnerable to cash flow challenges, especially with the long cash conversion cycle. The interest coverage ratio (ICR) is reported at 2.05, which, while above 2, suggests that the company can service its debt, albeit with limited room for error. Investors should also note the price-to-book value ratio of 0.91x, which indicates that the stock may be undervalued compared to its book value, but this could also reflect underlying concerns about future growth and profitability.
Shareholding Pattern and Investor Confidence
The shareholding structure of Concord Drugs Ltd indicates a significant level of control by promoters, who hold 54.39% of the equity, while public investors account for 45.61%. This ratio has shifted over recent quarters, with promoter holdings gradually increasing from 49% in December 2022. Such a trend can be interpreted as a sign of confidence from the management, potentially reassuring public investors. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may indicate limited institutional backing, which could be a concern for retail investors looking for stability. The number of shareholders increased to 4,718 recently, suggesting growing interest, but this must be weighed against the company’s operational challenges and profitability issues.
Outlook, Risks, and Final Insight
Looking ahead, Concord Drugs Ltd faces a complex landscape of opportunities and risks. The pharmaceutical sector’s inherent volatility, particularly in revenue generation and operational efficiency, poses a challenge. Investors should be cautious of the company’s fluctuating profitability metrics and extended cash conversion cycle, which could hinder operational cash flow. Additionally, while the increase in promoter shareholding can be seen as a positive signal, the absence of institutional support may raise concerns about long-term stability and growth. On the flip side, if the company can streamline operations and improve profitability, it may regain investor confidence. Retail investors might consider these factors carefully, weighing the potential for recovery against the backdrop of ongoing challenges in the pharmaceutical industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Concord Drugs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,110 Cr. | 377 | 479/192 | 85.1 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,580.32 Cr | 1,173.08 | 51.95 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.53 | 13.72 | 13.53 | 11.54 | 8.79 | 7.38 | 12.62 | 14.47 | 6.35 | 11.84 | 10.77 | 7.96 | 13.38 |
| Expenses | 11.56 | 12.53 | 12.08 | 10.80 | 7.39 | 5.85 | 12.06 | 14.28 | 5.62 | 11.05 | 9.45 | 7.03 | 12.44 |
| Operating Profit | 0.97 | 1.19 | 1.45 | 0.74 | 1.40 | 1.53 | 0.56 | 0.19 | 0.73 | 0.79 | 1.32 | 0.93 | 0.94 |
| OPM % | 7.74% | 8.67% | 10.72% | 6.41% | 15.93% | 20.73% | 4.44% | 1.31% | 11.50% | 6.67% | 12.26% | 11.68% | 7.03% |
| Other Income | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest | 0.34 | 0.42 | 0.45 | 0.42 | 0.39 | 0.39 | 0.43 | 0.38 | 0.37 | 0.39 | 0.43 | 0.53 | 0.42 |
| Depreciation | 0.39 | 0.53 | 0.38 | 0.31 | 0.38 | 0.38 | 0.38 | 0.39 | 0.34 | 0.34 | 0.37 | 0.37 | 0.37 |
| Profit before tax | 0.25 | 0.24 | 0.62 | 0.01 | 0.63 | 0.77 | -0.25 | -0.58 | 0.02 | 0.07 | 0.52 | 0.03 | 0.15 |
| Tax % | 28.00% | 25.00% | 25.81% | -600.00% | 23.81% | 31.17% | -4.00% | -39.66% | 50.00% | 28.57% | 57.69% | 33.33% | 26.67% |
| Net Profit | 0.19 | 0.18 | 0.45 | 0.07 | 0.49 | 0.53 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 |
| EPS in Rs | 0.22 | 0.21 | 0.51 | 0.08 | 0.53 | 0.57 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 |
Last Updated: August 19, 2025, 8:50 pm
Below is a detailed analysis of the quarterly data for Concord Drugs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 13.38 Cr.. The value appears strong and on an upward trend. It has increased from 7.96 Cr. (Mar 2025) to 13.38 Cr., marking an increase of 5.42 Cr..
- For Expenses, as of Jun 2025, the value is 12.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.03 Cr. (Mar 2025) to 12.44 Cr., marking an increase of 5.41 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.94 Cr.. The value appears strong and on an upward trend. It has increased from 0.93 Cr. (Mar 2025) to 0.94 Cr., marking an increase of 0.01 Cr..
- For OPM %, as of Jun 2025, the value is 7.03%. The value appears to be declining and may need further review. It has decreased from 11.68% (Mar 2025) to 7.03%, marking a decrease of 4.65%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.53 Cr. (Mar 2025) to 0.42 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Jun 2025, the value is 0.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.37 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.12 Cr..
- For Tax %, as of Jun 2025, the value is 26.67%. The value appears to be improving (decreasing) as expected. It has decreased from 33.33% (Mar 2025) to 26.67%, marking a decrease of 6.66%.
- For Net Profit, as of Jun 2025, the value is 0.11 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Mar 2025) to 0.11 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.11. The value appears strong and on an upward trend. It has increased from 0.01 (Mar 2025) to 0.11, marking an increase of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.95 | 40.02 | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 43.95 |
| Expenses | 30.72 | 32.99 | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 39.97 |
| Operating Profit | 3.23 | 7.03 | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 3.98 |
| OPM % | 9.51% | 17.57% | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 10.21% | 9.06% |
| Other Income | 0.12 | 0.37 | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest | 1.78 | 2.72 | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.77 |
| Depreciation | 1.14 | 3.63 | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.42 | 1.45 |
| Profit before tax | 0.43 | 1.05 | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 0.77 |
| Tax % | 20.93% | 33.33% | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | 54.69% | |
| Net Profit | 0.34 | 0.70 | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.30 | 0.39 |
| EPS in Rs | 0.47 | 0.97 | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.30 | 0.39 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 105.88% | 150.00% | -90.86% | 100.00% | 28.12% | -19.51% | 893.94% | -51.52% | -44.03% | -52.81% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 44.12% | -240.86% | 190.86% | -71.88% | -47.64% | 913.45% | -945.46% | 7.50% | -8.78% | 24.24% |
Concord Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -6% |
| 3 Years: | -14% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -2% |
| 3 Years: | -43% |
| TTM: | 880% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 29% |
| 3 Years: | 26% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: October 10, 2025, 3:48 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.24 | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 |
| Reserves | 7.33 | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 |
| Borrowings | 17.31 | 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 |
| Other Liabilities | 12.80 | 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 |
| Total Liabilities | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 |
| Fixed Assets | 20.84 | 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 2.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 |
| Other Assets | 23.84 | 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 |
| Total Assets | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 |
Below is a detailed analysis of the balance sheet data for Concord Drugs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 24.11 Cr.. The value appears strong and on an upward trend. It has increased from 23.82 Cr. (Mar 2024) to 24.11 Cr., marking an increase of 0.29 Cr..
- For Borrowings, as of Mar 2025, the value is 16.91 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 14.93 Cr. (Mar 2024) to 16.91 Cr., marking an increase of 1.98 Cr..
- For Other Liabilities, as of Mar 2025, the value is 7.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.55 Cr. (Mar 2024) to 7.56 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Mar 2025, the value is 58.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 56.30 Cr. (Mar 2024) to 58.58 Cr., marking an increase of 2.28 Cr..
- For Fixed Assets, as of Mar 2025, the value is 12.17 Cr.. The value appears strong and on an upward trend. It has increased from 11.63 Cr. (Mar 2024) to 12.17 Cr., marking an increase of 0.54 Cr..
- For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.63 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 0.37 Cr..
- For Investments, as of Mar 2025, the value is 1.62 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.62 Cr..
- For Other Assets, as of Mar 2025, the value is 42.79 Cr.. The value appears strong and on an upward trend. It has increased from 41.42 Cr. (Mar 2024) to 42.79 Cr., marking an increase of 1.37 Cr..
- For Total Assets, as of Mar 2025, the value is 58.58 Cr.. The value appears strong and on an upward trend. It has increased from 56.30 Cr. (Mar 2024) to 58.58 Cr., marking an increase of 2.28 Cr..
Notably, the Reserves (24.11 Cr.) exceed the Borrowings (16.91 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.08 | -14.24 | -11.69 | -9.93 | -8.84 | -6.18 | -6.23 | -9.75 | -10.84 | -11.29 | -11.25 | -13.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 180.83 | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 |
| Inventory Days | 65.28 | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 |
| Days Payable | 140.64 | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 |
| Cash Conversion Cycle | 105.47 | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 285.41 | 332.82 |
| Working Capital Days | 55.48 | 68.04 | 113.14 | 4.00 | 79.27 | 102.33 | 103.37 | 140.30 | 112.48 | 145.12 | 126.56 | 134.22 |
| ROCE % | 7.15% | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 5.97% | 4.48% | 4.73% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Diluted EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Cash EPS (Rs.) | 1.77 | 2.03 | 2.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Revenue From Operations / Share (Rs.) | 45.24 | 44.92 | 55.91 |
| PBDIT / Share (Rs.) | 4.15 | 4.05 | 4.92 |
| PBIT / Share (Rs.) | 2.72 | 2.50 | 3.17 |
| PBT / Share (Rs.) | 0.69 | 0.62 | 1.34 |
| Net Profit / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| NP After MI And SOA / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| PBDIT Margin (%) | 9.16 | 9.01 | 8.79 |
| PBIT Margin (%) | 6.00 | 5.55 | 5.67 |
| PBT Margin (%) | 1.52 | 1.40 | 2.39 |
| Net Profit Margin (%) | 0.74 | 1.05 | 1.89 |
| NP After MI And SOA Margin (%) | 0.74 | 1.05 | 1.89 |
| Return on Networth / Equity (%) | 0.98 | 1.39 | 3.10 |
| Return on Capital Employeed (%) | 6.97 | 6.66 | 8.07 |
| Return On Assets (%) | 0.51 | 0.80 | 1.69 |
| Long Term Debt / Equity (X) | 0.03 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.50 | 0.49 | 0.50 |
| Asset Turnover Ratio (%) | 0.73 | 0.76 | 0.00 |
| Current Ratio (X) | 1.56 | 2.09 | 2.01 |
| Quick Ratio (X) | 0.59 | 1.02 | 1.08 |
| Inventory Turnover Ratio (X) | 1.88 | 2.09 | 0.00 |
| Interest Coverage Ratio (X) | 2.05 | 2.17 | 2.68 |
| Interest Coverage Ratio (Post Tax) (X) | 1.17 | 1.25 | 1.58 |
| Enterprise Value (Cr.) | 48.05 | 51.59 | 41.61 |
| EV / Net Operating Revenue (X) | 1.06 | 1.15 | 0.79 |
| EV / EBITDA (X) | 11.58 | 12.73 | 9.08 |
| MarketCap / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| Price / BV (X) | 0.91 | 1.04 | 0.80 |
| Price / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 |
After reviewing the key financial ratios for Concord Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.77. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.77, marking a decrease of 0.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 45.24. It has increased from 44.92 (Mar 24) to 45.24, marking an increase of 0.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 4.15. This value is within the healthy range. It has increased from 4.05 (Mar 24) to 4.15, marking an increase of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has increased from 2.50 (Mar 24) to 2.72, marking an increase of 0.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 0.69, marking an increase of 0.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For PBDIT Margin (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 10. It has increased from 9.01 (Mar 24) to 9.16, marking an increase of 0.15.
- For PBIT Margin (%), as of Mar 25, the value is 6.00. This value is below the healthy minimum of 10. It has increased from 5.55 (Mar 24) to 6.00, marking an increase of 0.45.
- For PBT Margin (%), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 10. It has increased from 1.40 (Mar 24) to 1.52, marking an increase of 0.12.
- For Net Profit Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 8. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 15. It has decreased from 1.39 (Mar 24) to 0.98, marking a decrease of 0.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.97. This value is below the healthy minimum of 10. It has increased from 6.66 (Mar 24) to 6.97, marking an increase of 0.31.
- For Return On Assets (%), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 5. It has decreased from 0.80 (Mar 24) to 0.51, marking a decrease of 0.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 0.50, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.76 (Mar 24) to 0.73, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.56, marking a decrease of 0.53.
- For Quick Ratio (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.59, marking a decrease of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 4. It has decreased from 2.09 (Mar 24) to 1.88, marking a decrease of 0.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.05. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 2.05, marking a decrease of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 3. It has decreased from 1.25 (Mar 24) to 1.17, marking a decrease of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 48.05. It has decreased from 51.59 (Mar 24) to 48.05, marking a decrease of 3.54.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.15 (Mar 24) to 1.06, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.58. This value is within the healthy range. It has decreased from 12.73 (Mar 24) to 11.58, marking a decrease of 1.15.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For Price / BV (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.91, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Concord Drugs Ltd:
- Net Profit Margin: 0.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.97% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.98% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.59
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 142 (Industry average Stock P/E: 51.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.5
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.249, R R District Telangana 501511 | concorddrugsltd@gmail.com http://www.concorddrugs.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Nagi Reddy | Chairman & Managing Director |
| Mr. S Manoj Kumar Reddy | Whole Time Director |
| Mr. S Koni Reddy | WholeTime Director & CFO |
| Mr. K Ramachandra Reddy | Independent Director |
| Ms. Sumeela Kasu | Independent Director |
| Mr. S Nagavenkata Hareesh | Independent Director |
FAQ
What is the intrinsic value of Concord Drugs Ltd?
Concord Drugs Ltd's intrinsic value (as of 06 December 2025) is 35.08 which is 53.54% lower the current market price of 75.50, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 75.5 Cr. market cap, FY2025-2026 high/low of 92.5/26.1, reserves of ₹24.11 Cr, and liabilities of 58.58 Cr.
What is the Market Cap of Concord Drugs Ltd?
The Market Cap of Concord Drugs Ltd is 75.5 Cr..
What is the current Stock Price of Concord Drugs Ltd as on 06 December 2025?
The current stock price of Concord Drugs Ltd as on 06 December 2025 is 75.5.
What is the High / Low of Concord Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Concord Drugs Ltd stocks is 92.5/26.1.
What is the Stock P/E of Concord Drugs Ltd?
The Stock P/E of Concord Drugs Ltd is 142.
What is the Book Value of Concord Drugs Ltd?
The Book Value of Concord Drugs Ltd is 34.4.
What is the Dividend Yield of Concord Drugs Ltd?
The Dividend Yield of Concord Drugs Ltd is 0.00 %.
What is the ROCE of Concord Drugs Ltd?
The ROCE of Concord Drugs Ltd is 4.73 %.
What is the ROE of Concord Drugs Ltd?
The ROE of Concord Drugs Ltd is 0.88 %.
What is the Face Value of Concord Drugs Ltd?
The Face Value of Concord Drugs Ltd is 10.0.